Video

Dr. Chi on Study of Tazemetostat in Children With INI1-Negative Tumors

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of Pediatrics, Harvard Medical School, discusses a phase I multicenter trial of tazemetostat in children with INI1-negative tumors.

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses a phase I multicenter trial of tazemetostat in children with INI1-negative tumors.

Investigators are evaluating the EZH2 inhibitor tazemetostat in children with relapsed or refractory INI1-negative tumors including rhabdoid tumors, epithelioid sarcoma, chordoma, and synovial sarcoma. The use of tazemetostat in this population makes sense, explains Chi, as EZH2 is one unit in a multi-unit complex called polycomb repressive complex 2 (PRC2). PRC2 works antagonistically to the SWI/SNF complex, of which INI1 is a member.

This is the first time that tazemetostat has been used in children, and the first time that EZH2 has been tested in children. In the phase I trial, tazemetostat was dosed continuously as an oral suspension administered twice daily in patients aged 6 months to 21 years. Chi says that this has been a collaborative effort, and the study is now moving into a dose-expansion phase based on positive safety signals in the phase I trial.

Related Videos
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Saro H. Armenian, DO, MPH
Saro H. Armenian, DO, MPH
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.